Beta-adrenoblokatory v lechenii infarkta miokarda i stabil'noy ishemicheskoy bolezni serdtsa: spornye voprosy i neoproverzhimye dokazatel'stva


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review article presents the current data on the effect of beta-adrenoblockers on clinical outcomes in patients with myocardial infarction and stable coronary artery disease. The data are represented in accordance with recent Recommendations of International Cardiological Societies. Statements with high-class and high-level of evidence are described; controversial issues of use of beta-adrenoblockers in CAD patients in special clinical situations are emphasized.

Full Text

Restricted Access

About the authors

N. A Koziolova

Email: nakoziobva@mail.ru

References

  1. Go AS, Iribarren C, Chandra M, et al. Statin and beta-blocker therapy and the initial presentation of coronary heart disease. Ann Intern Med 2006;144(4):229-38
  2. Manrique C, Giles TD, Ferdinand KC, Sowers JR. Review Realities of newer beta-blockers for the management of hypertension. J Clin Hypertens (Greenwich). 2009; 11(7):369-75.
  3. Design of the Beta-Blocker Evaluation Survival Trial (BEST). The BEST Steering Committee. Am J Cardiol. 1995;75( 17):1220-23.
  4. DiLenarda A, Gregori D, Sinagra G, et al. Metoprolol in dilated cardiomyopathy: is it possible to identify factors predictive of improvement? The Heart Muscle Disease Study Group. J Card Fail 1996;2(2): 87-102.
  5. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004;364(9446): 1684-89.
  6. Aursnes I, Osnes JB, Tvete IF, et al. Does atenolol differ from other beta-adrenergic blockers? BMC Clin Pharmacol 2007;7:4.
  7. Carville S, Harker M, Henderson R, Gray H; et al. Acute management of myocardial infarction with ST-segment elevation: summary of NICE guidance. Guideline Development Group. BMJ. 20130;347:4006.
  8. Anderson JL, Adams CD, Antman EM, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61 (23):1 79-347.
  9. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol 2013;61 (4):78-140.
  10. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33 (20):2569-619.
  11. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32(23):2999-3054.
  12. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1622-32.
  13. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) II-B Study. Circulation 1991;83 :422-37.
  14. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986;2:57-66.
  15. A randomized trial of propranolol in patients with acute myocardial infarction, I: mortality results. JAMA. 1982;247:1707-14.
  16. Freemantle N, Cleland J, Young P, et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-37.
  17. Waagstein F, Hjalmarson AC, Wasir HS. Apex cardiogram and systolic time intervals in acute myocardial infarction and effect of practolol. Br Heart J 1974;1109-21.
  18. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 1981;823-27.
  19. Richterova A, Herlitz J, Holmberg S, et al. The Goteborg Metoprolol Trial in Acute Myocardial Infarction. Effects on chest pain. Am J Cardiol 1984;53:32-36.
  20. Norris RM, Brown MA, Clarke ED, et al. Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. Lancet 1984;2:883-86.
  21. The MIAMI Trial Research Group: Metoprolol in acute myocardial infarction (MIAMI). Am J Cardiol 1985;56:1-57.
  22. Ryden L, Ariniego R, Arnman K, et al. A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. N Engl J Med 1983;308: 614-18.
  23. Yusuf S, Lessem J, Pet J, et al. Primary and secondary prevention of myocardial infarction and strokes. An update of randomly allocated controlled trials. J Hypertens 1993;11(Suppl. 4):61-73.
  24. Borrello F, Beahan M, Klein L, Gheorghiade M. Reappraisal of beta-blocker therapy in the acute and chronic post-myocardial infarction period. Rev Cardiovasc Med. 2003;4 Suppl 3:13-24.
  25. Everly MJ, Heaton PC, Cluxton RJ Jr. Beta-blocker underuse in secondary prevention of myocardial infarction. Ann Pharmacother 2004;38(2):286-93.
  26. El-Menyar A, Ahmed E, Albinali H, et al. Mortality trends in women and men presenting with acute coronary syndrome: insights from a 20-year registry. PLoS One 2013;8(7):70066.
  27. Voss J, Martin A, Caldwell I, et al. How long do acute coronary syndrome patients wait for reperfusion, diagnostic coronary angiography and surgical revascularisation? N Z Med J 2013;126(1376):38-48.
  28. Van de Werf F, Janssens L, Brzostek T, et al. Short term effect of early intravenous treatment with beta-adrenergic blocking agents or a specific bradycardia agent in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol 1993;22:407-16.
  29. Barron HV, Rundle AC, Gore JM, et al. for the Participants in the national registry of myocardial infarction-2. Intracranial hemorrhage rates and effect of immediate beta-blocker use in patients with acute myocardial infarction treated with tissue plasminogen activator. Am J Cardiol 2000;85:294-98.
  30. Emery M, Lopez-Sendon J, Steg PG, et al. Patterns of use and potential impact of early beta-blocker therapy in non-ST-elevation myocardial infarction with and without heart failure: the Global Registry of Acute Coronary Events. Am Heart J. 2006;152(6): 1015-21.
  31. Miller CD, Roe MT, Mulgund J, et al. Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction. Am J Med. 2007;120(8): 685-92.
  32. Hirschl MM, Wollmann CG, Erhart F, et al. Benefit of immediate beta-blocker therapy on mortality in patients with ST-segment elevation myocardial infarction. Crit Care Med. 2013;41(6):1396-404.
  33. Pfisterer M, Cox JL, Granger CG, et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction. The GUSTO-I experience. Global utilization of streptokinase and TPA (alteplase) for occluded coronary arteries. J Am Coll Cardiol 1998;32:634-40.
  34. Harjai KJ, Stone GW, Boura J, et al. Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction. Am J Cardiol 2003;91:655-60.
  35. Halkin A, Nikolsky E, Aymong E, et al. The survival benefit of periprocedural beta-blockers in patients with acute myocardial infarction undergoing primary angioplasty is determined by use of these drugs before admission. Am J Cardiol 2003;92(Suppl. L):228.
  36. Kernis SJ, Arguya KJ, Boura J, et al. Does beta-bloquer therapy improbe clinical outcomes of acute myocardial infarction after successful primary angioplasty? A pooled analisis from the primary angioplasti in myocardial infarction-2 (PAMI-2), No surgery on-site (noSOS), stetn PAMI and Air PAMI trials. Circulation 2003;108(Suppl. IV):416-17.
  37. Kernis SJ, Harjai KJ, Stone GW, et al. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol 2004;43(10): 1773-79.
  38. Effect of metoprolol on death and cardiac events during a 2-year period after coronary artery bypass grafting. The MACB Study Group. Eur Heart J 1995;16(12):1825-32.
  39. Geraci SA, Haan CK. Effect of beta blockers after coronary artery bypass in postinfarct patients: what can we learn from available literature? Ann Thorac Surg 2002; 74(5): 172 7-32.
  40. CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385-90.
  41. Adler A, Greenberg BH. Use of Beta Blockers in Patients with Post-MI Left Ventricular Dysfunction.Curr Treat Options Cardiovasc Med 2004;6(4):335-43.
  42. Avanzini F, Zuanetti G, Latini R, et al. Use of beta-blocking agents in secondary prevention after myocardial infarction: A case for evidence-based medicine? Eur Heart J 1997;18(9):1447-56.
  43. Gislason G, Rasmussen J, Abildstrom S, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006;27(10):1153-58.
  44. Thompson PL. Should в-blockers still be routine after myocardial infarction? Curr Opin Cardiol 2013;28(4):399-404.
  45. Kezerashvili A, Marzo K, De Leon J. Beta blocker use after acute myocardial infarction in the patient with normal systolic function: when is it «ok» to discontinue? Curr Cardiol Rev 2012;8(1):77-84.
  46. Wienbergen H, Zeymer U, Gitt AK, et al. Prognostic impact of acute beta-blocker therapy on top of aspirin and angiotensin-converting enzyme inhibitor therapy in consecutive patients with ST-elevation acute myocardial infarction. Am J Cardiol 2007; 99(9):1208-11.
  47. Nakatani D, Sakata Y, Suna S, et al. Impact of beta blockade therapy on long-term mortality after ST-segment elevation acute myocardial infarction in the percutaneous coronary intervention era. Am J Cardiol 2013; 111 (4):457-64.
  48. Ozasa N, Kimura T, Morimoto T, et al. Lack of effect of oral beta-blocker therapy at discharge on long-term clinical outcomes of ST-segment elevation acute myocardial infarction after primary percutaneous coronary intervention. Am J Cardiol 2010;106(9): 1225-33.
  49. Bangalore S, Steg G, Deedwania P, et al. в-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): 1340-49.
  50. Ducrocq G, Bhatt D, Labreuche J, et al. Geographic differences in outcomes in outpatients with established atherothrombotic disease: Results from the REACH Registry.Eur J Prev Cardiol 2013 Aug 21.
  51. Ohman EM, Bhatt DL, Steg PG, et al. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 2006; 151 (4):786-10.
  52. Kelsey JL, Thompson WD, Evans AL. Methods in Observational Epidemiology. N.-Y., 1986.
  53. Shin J, Johnson JA. Pharmacogenetics of в-Blockers Pharmacotherapy. Author manuscript; available in PMC 2009 September
  54. Published in final edited form as: Pharmacotherapy 2007;27(6):874-87.
  55. Parker ED, Margolis KL, Trower NK, et al. Comparative effectiveness of 2 β-blockers in hypertensive patients. Arch Intern Med 2012;172(18):1406-12.
  56. Harris PR, Stein PK, Fung GL, Drew BJ. Prognostic value of heart rate turbulence for risk assessment in patients with unstable angina and non-ST elevation myocardial infarction. Vasc Health Risk Manag 2013;9:465-73.
  57. Feldman D, Elton TS, Menachemi DM, Wexler RK. Heart rate control with adrenergic blockade: Clinical outcomes in cardiovascular medicine. Vasc Health Risk Manag 2010;6:387-97.
  58. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295(2):180-89.
  59. Rutten FH, Groenwold RH. в-Blocker use for patients with or at risk for coronary artery disease. JAMA. 2013;309(5):438-39.
  60. Costagliola D, Hernin MA. в-Blocker use for patients with or at risk for coronary artery disease. JAMA 2013;309(5):439.
  61. Brown JR, Conley SM, Niles NW 2nd. Predicting Readmission or Death After Acute ST-Elevation Myocardial Infarction. Clin Cardiol 2013;Jun 10.
  62. Gunnell AS, Einarsdottir K, Sanfilippo F, et al. Improved long-term survival in patients on combination therapies following an incident acute myocardial infarction: a longitudinal population-based study. Heart 2013;99( 18):1353-58.
  63. Smith SC Jr., Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011;124:2458-73.
  64. Wang TJ, Stafford RS. National patterns and predictors of betablocker use in patients with coronary artery disease. Arch. Int. Med. 1998;158:1901-906.
  65. Boudonas GE. в-Blockers in coronary artery disease management. Hippokratia 2010;14(4):231-35.
  66. Cuculi F, Radovanovic D, Pedrazzini G, et al. Is pretreatment with Beta-blockers beneficial in patients with acute coronary syndrome? Cardiology 2010;115:91-7.
  67. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012;60(24):44-164.
  68. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-55.
  69. Leizorovicz A, Lechat P, Cucherat M, et al. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies-CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. Am Heart J 2002; 143:301 -07.
  70. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.
  71. Domanski MJ, Krause-Steinrauf H, Massie BM, et al. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail. 2003;9:354-63.
  72. Goldstein S. Beta-blocking drugs and coronary heart disease. Cardiovasc Drugs Ther 1997;11 (Suppl 1):219-25.
  73. Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004;25:1341-62.
  74. Hall SL, Lorenc T. Secondary prevention of coronary artery disease. Am Fam Physician 2010;8:289-96.
  75. Frishman WH, Heiman M, Soberman J, et al. Comparison of celiprolol and propranolol in stable angina pectoris. Celiprolol International Angina Study Group. Am J Cardiol 1991;67:665-70.
  76. Narahara KA. Double-blind comparison of once daily betaxolol versus propranolol four times daily in stable angina pectoris. Betaxolol Investigators Group. Am J Cardiol 1990;65:577-82.
  77. Rehnqvist N, Hjemdahl P, Billing E, et al. Effects of metoporlol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (ASPIS) Eur Heart J 1996;17:76-81.
  78. Dargie HJ, Ford I, Fox KM. Total Ischaemic Barden European Trial (TIBET). Effects of ischaemia and treatment with atenolol nifedipin SR and their combination on outcome in patients with chronic angina. The TIBET Study Group. Eur Heart J 1996;17:104-112.
  79. Ryden L. Efficacy of epanolol versus metoprolol in angina pectoris: report from a Swedish multicentre study of exercise tolerance. J Intern Med 1992;231:7-11.
  80. Boberg J, Larsen FF, Pehrsson SK. The effects of beta blockade with (epanolol) and without (atenolol) intrinsic sympathomimetic activity in stable angina pectoris. The Visacor Study Group. Clin Cardiol 1992;15:591-95.
  81. Rollins G. Calcium antagonist and beta blocker regimens found equally effective in hypertensive patients with coronary artery disease. Rep Med Guidel Outcomes Res 2004; 15(2):1, 5-6.
  82. Klein WW, Jackson G, Tavazzi L. Efficacy of monotherapy compared with combined anti-anginal drugs in the treatment of chronic stable angina pectoris: a meta-analysis. Coron Artery Dis 2002;13(8):427-36.
  83. Zuckerman IH, Yin X, Rattinger GB, et al. Effect of exposure to evidence-based pharmacotherapy on outcomes after acute myocardial infarction in older adults. J Am Geriatr Soc 2012;60( 10):1854-61.
  84. Shu de F, Dong BR, Lin XF et al. Long-term beta blockers for stable angina: systematic review and meta-analysis. Eur J Prev Cardiol 2012;19(3):330-41.
  85. Bunch TJ, Muhlestein JB, Bair TL, et al. Effect of beta-blocker therapy on mortality rates and future myocardial infarction rates in patients with coronary artery disease but no history of myocardial infarction or congestive heart failure. Am J Cardiol 2005;95(7):827-31.
  86. Vidal-Perez R, Otero-Ravi a F, Franco M, et al. Determinants of cardiovascular mortality in a cohort of primary care patients with chronic ischemic heart disease. BARBANZA Ischemic Heart Disease (BARIHD) study. Int J Cardiol 2013;167(2):442-50.
  87. Ozasa N, Morimoto T, Bao B, et al. в-blocker use in patients after percutaneous coronary interventions: One size fits all? Worse outcomes in patients without myocardial infarction or heart failure. Int J Cardiol 2012 pii:0167-5273( 12)01374-75.
  88. Lau WC, Froehlich JB, Jewell ES, et al. Impact of adding aspirin to beta-blocker and statin in high-risk patients undergoing major vascular surgery. Ann Vasc Surg 2013;27(4):537-45.
  89. Mercando AD, Lai HM, Aronow WS, et al. Reduction in atherosclerotic events: a retrospective study in an outpatient cardiology practice. Arch Med Sci 2012;8(1):57-62.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies